Based on the above statements and comprehensive validations, we suggest that the novel TGF-β pathway clusters which were closed in conjunction with COMP in our study are reliable and have potential for leading novel immunological therapies and improving CRC patient prognosis. Here, COMP is linked to colorectal carcinoma.